Jump to content

Long-Acting Antibody treatment to be provided to those suffering immunodeficiency


snoop1130

Recommended Posts

TSNBg3wSBdng7ijMhwlOeCWcc9PyfmngNxuV2PXrUcf-768x512.jpg

 

Thailand’s Ministry of Public Health and AstraZeneca (Thailand) signed a contract today (Wednesday) for the procurement of 257,500 doses of Long-Acting Antibodies (LAAB) for people who suffer from immunodeficiency, to reduce of risk of becoming gravely ill if infected with COVID-19.

 

Public Health Minister Anutin Charnvirakul said that the acquisition of the LAAB medication does not require any additional budget, because the new contract will amend the previous AstraZeneca vaccine procurement contract, replacing some of the vaccine to be supplied with LAAB medication.

 

He explained that LAAB will be administered to people who suffer from immunodeficiency, to reduce their risk of becoming seriously ill or dying if they catch COVID-19, such as those with chronic kidney disease or those who have undergone organ transplantation and require immunosuppressant medication, adding that patients with chronic kidney disease have been dying every day.

 

Full Story: https://www.thaipbsworld.com/long-acting-antibody-treatment-to-be-provided-to-those-suffering-immunodeficiency/

 

Logo-top-.png

-- © Copyright Thai PBS 2022-07-06
 

- Cigna offers a range of visa-compliant plans that meet the minimum requirement of medical treatment, including COVID-19, up to THB 3m. For more information on all expat health insurance plans click here.

 

Monthly car subscription with first-class insurance, 24x7 assistance and more in one price - click here to find out more!

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Recently Browsing   0 members

    • No registered users viewing this page.




  • Popular Now

×
×
  • Create New...